Reviva prices $10M public offering of 20M shares and warrants at $0.50 per unit

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Offering comprises 20M shares, 20M Series C warrants (5-year, $0.50 exercise), and 20M Series D warrants (12-month, $0.50 exercise).
Gross proceeds of $10M; net proceeds expected ~$9.0M after fees.
Net proceeds to fund R&D, working capital, and general corporate purposes.
Closing expected June 27, 2025; 60-day lock-up on share issuance and one-year variable rate transaction restriction.
A.G.P./Alliance Global Partners serving as sole placement agent with 7.0% cash fee.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.